#Belantamab is being WITHDRAWN as a Rx for refractory multiple myeloma (accelerated approval in August 2020 off #DREAMM2).

#DREAMM3: Ph3,N=320, belanta vs Pom/Dex after ≥2 Rx.
- No PFS/OS benefit
- similar ORR
- Belanta had ophthalmologic AEs

#mmsm #BCMA #OncEd #oncology #MedMastodon #myeloma

The #BCMA #ADC belanatamab mafodin-blmf was withdrawn from the US (#AcceleratedApproval in August 2008) after DREAMM-3 P3 confirmatory trial (belantamab vs. PomDex) for patients with #RRMM showed that PFS did not reach statistical significance (11.2 vs 7 months; HR, 1.03; 95% CI, 0.72 – 1.47). Another example that #FDA #AcceleratedApproval mechanism works as it should!!!

https://www.medscape.com/viewarticle/984437